US2019211081A1PendingUtilityA1

Antibody constant region variant

67
Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Mar 19, 2009Filed: Mar 11, 2019Published: Jul 11, 2019
Est. expiryMar 19, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Tomoyuki IgawaTaichi KuramochiAtsuhiko MaedaHirotake Shiraiwa
C07K 16/2875C07K 16/2866C07K 2317/515C07K 2317/52C07K 2317/71C07K 2317/528C07K 2317/522C07K 2317/524C07K 2317/72C07K 2317/76C07K 2317/526C07K 2317/92C07K 2317/94C07K 16/00C07K 2317/53C07K 16/40C07K 16/2896
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A human λ chain constant region variant comprising the amino acid sequence of SEQ ID NO: 37 in which either
 (a) at least one amino acid at any of positions 99 to 103 in the amino acid sequence of SEQ ID NO: 37 is deleted, and optionally any other amino acid at any of positions 1 to 103 of SEQ ID NO: 37 is substituted with another amino acid, wherein the total number of deleted amino acids is one to five and the combined total number of deleted amino acids and substituted amino acids is 20 or fewer; or 
 (b) Cys at position 104 of SEQ ID NO: 37 is deleted or substituted with another amino acid, and optionally at least one amino acid at any of positions 1 to 103 of SEQ ID NO: 37 is deleted or substituted with another amino acid, provided that at least one amino acid at any of positions 99 to 103 of SEQ ID NO: 37 is substituted with Cys, wherein the total number of deleted amino acids is up to five and the combined total number of deleted amino acids and substituted amino acids is 20 or fewer. 
 
     
     
         23 . The human λ chain constant region variant of  claim 22 , wherein the amino acid at position 102 in the amino acid sequence of SEQ ID NO: 37 is deleted. 
     
     
         24 . The human λ chain constant region variant of  claim 22 , wherein the amino acid at position 103 in the amino acid sequence of SEQ ID NO: 37 is deleted. 
     
     
         25 . A human λ chain constant region variant comprising the amino acid sequence of SEQ ID NO: 37 in which at least one amino acid at any of positions 99 to 103 is substituted with Cys, and Cys at position 104 of SEQ ID NO: 37 is deleted or substituted with another amino acid. 
     
     
         26 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 22 . 
     
     
         27 . A pharmaceutical composition comprising the antibody of  claim 26 . 
     
     
         28 . The human λ chain constant region variant of  claim 22 , comprising the amino acid sequence of SEQ ID NO: 37 with Cys at position 104 deleted and a Cys substituted at one or more of positions 99 to 103. 
     
     
         29 . The human λ chain constant region variant of  claim 22 , wherein only one of positions 99 to 103 of SEQ ID NO: 37 is a Cys. 
     
     
         30 . The human λ chain constant region variant of  claim 28 , wherein only one of positions 99 to 103 of SEQ ID NO: 37 is a Cys. 
     
     
         31 . The human λ chain constant region variant of  claim 22 , wherein the amino acids at two of positions 99 to 103 of SEQ ID NO: 37 are substituted with Cys. 
     
     
         32 . The human λ chain constant region variant of  claim 28 , wherein the amino acids at two of positions 99 to 103 of SEQ ID NO: 37 are substituted with Cys. 
     
     
         33 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 23 . 
     
     
         34 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 24 . 
     
     
         35 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 25 . 
     
     
         36 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 28 . 
     
     
         37 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 29 . 
     
     
         38 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 30 . 
     
     
         39 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 31 . 
     
     
         40 . An antibody comprising a light chain comprising the human λ chain constant region variant of  claim 32 . 
     
     
         41 . The antibody of  claim 26 , wherein disulfide bond pattern heterogeneity of the human λ chain constant region variant in the antibody is reduced compared to disulfide bond pattern heterogeneity of a reference human λ chain constant region in a reference antibody that is identical to the antibody of  claim 26  except that the reference human λ chain constant regions in the reference antibody each consists of the amino acid sequence of SEQ ID NO: 37. 
     
     
         42 . The human λ chain constant region variant of  claim 22 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         43 . The human λ chain constant region variant of  claim 23 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         44 . The human λ chain constant region variant of  claim 24 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         45 . The antibody of  claim 26 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         46 . The pharmaceutical composition of  claim 27 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         47 . The human λ chain constant region variant of  claim 29 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         48 . The human λ chain constant region variant of  claim 31 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         49 . The antibody of  claim 33 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         50 . The antibody of  claim 34 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         51 . The antibody of  claim 37 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         52 . The antibody of  claim 39 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         53 . The antibody of  claim 41 , wherein the human λ chain constant region variant comprises the amino acid sequence of SEQ ID NO: 37 except at one or more positions within positions 99 to 103 of SEQ ID NO: 37. 
     
     
         54 . The human λ chain constant region variant of  claim 22 , wherein the combined total number of deleted or substituted amino acids is 10 or fewer. 
     
     
         55 . A human λ chain constant region variant that is 99-104 amino acid residues in length, comprises at least one Cys residue at a position or positions selected from positions 99-103, and does not comprise a Cys residue at position 104, wherein the variant comprises SEQ ID NO: 37 with a combined total of up to 20 substitutions or deletions. 
     
     
         56 . The variant of  claim 55 , wherein the variant comprises SEQ ID NO: 37 with a combined total of up to 10 substitutions or deletions.

Join the waitlist — get patent alerts

Track US2019211081A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.